Cita APA (7a ed.)
Moya-Alarcon, C., Gonzalez-Dominguez, A., Ivanova-Markova, Y., Gimeno-Ballester, V., Barretina-Ginesta, M., Perez-Fidalgo, J., & Redondo, A. (2022). Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain? ACADEMIC PRESS INC ELSEVIER SCIENCE.
Cita Chicago Style (17a ed.)
Moya-Alarcon, C., A. Gonzalez-Dominguez, Y. Ivanova-Markova, V. Gimeno-Ballester, MP Barretina-Ginesta, JA Perez-Fidalgo, y A. Redondo. Olaparib as First Line in BRCA-mutated Advanced Ovarian Carcinoma: Is It Cost-effective in Spain? ACADEMIC PRESS INC ELSEVIER SCIENCE, 2022.
Cita MLA (9a ed.)
Moya-Alarcon, C., et al. Olaparib as First Line in BRCA-mutated Advanced Ovarian Carcinoma: Is It Cost-effective in Spain? ACADEMIC PRESS INC ELSEVIER SCIENCE, 2022.
Precaución: Estas citas no son 100% exactas.